Skip to main content
logo
Protagenic Therapeutics, Inc. (PTIX)
OTCMKTS · Delayed Price · Currency is USD
1.190
-0.010 (-0.83%)
At close: Sep 1, 2026

Protagenic Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Apr - Mar.

Operating Activities

Fiscal Year
TTMFY 2026FY 2025
Period Ending
Jun '26 Mar '26 Mar '25
Net Income
5.461.37-3.59
Depreciation & Amortization
0.040.05-
Other Amortization
1.321.570.6
Loss (Gain) From Sale of Assets
-7.31-7.31-
Stock-Based Compensation
0.360.42-
Provision & Write-off of Bad Debts
--0.77
Other Operating Activities
-2.52-0.050.1
Change in Inventory
0-0-0
Change in Accounts Payable
0.821.040.18
Change in Other Net Operating Assets
-0.190.110.17
Operating Cash Flow
-2-2.81-1.77
Operating Cash Flow Growth
---

Investing Activities

Fiscal Year
TTMFY 2026FY 2025
Period Ending
Jun '26 Mar '26 Mar '25
Capital Expenditures
-0-0-
Cash Acquisitions
-0.310.63-
Investing Cash Flow
-0.310.63-

Financing Activities

Fiscal Year
TTMFY 2026FY 2025
Period Ending
Jun '26 Mar '26 Mar '25
Short-Term Debt Issued
-0.061.81
Total Debt Issued
-0.60.061.81
Short-Term Debt Repaid
--0.53-
Total Debt Repaid
-0.53-0.53-
Net Debt Issued (Repaid)
-1.13-0.471.81
Issuance of Common Stock
-4.350
Financing Cash Flow
-1.133.871.81

Net Cash Flow

Fiscal Year
TTMFY 2026FY 2025
Period Ending
Jun '26 Mar '26 Mar '25
Foreign Exchange Rate Adjustments
-0.08-0.2-0.03
Net Cash Flow
-3.531.490.01

Free Cash Flow

Fiscal Year
TTMFY 2026FY 2025
Period Ending
Jun '26 Mar '26 Mar '25
Free Cash Flow
-2-2.81-1.77
Free Cash Flow Growth
---
Free Cash Flow Per Share
-1.08-1.21-0.33
Levered Free Cash Flow
-7.06-3.24-
Unlevered Free Cash Flow
-7.6-3.87-

Additional Metrics

Fiscal Year
TTMFY 2026FY 2025
Period Ending
Jun '26 Mar '26 Mar '25
Change in Working Capital
0.631.150.35